{"id":"W4242040300","doi":"10.1200/jco.2021.39.3_suppl.94","title":"LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Irinotecan; Internal medicine; Colorectal cancer; Oncology; Clinical endpoint; Oxaliplatin; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003416358,0.00213543,0.001997048,0.0005785446,0.000630634,0.001343274,0.001104707,0.00115329,0.004384317],"category_scores_gemma":[0.001367784,0.0008958669,0.001715149,0.0005141287,0.001119292,0.001152324,0.0006962446,0.002547572,0.001204425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001356589,"about_ca_system_score_gemma":0.00195335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001486915,"about_ca_topic_score_gemma":0.002302229,"domain_scores_codex":[0.9990227,0.0005140612,0.00004864224,0.000176002,0.00008406149,0.0001544978],"domain_scores_gemma":[0.9986972,0.0001724044,0.0002536246,0.0001353016,0.00007634475,0.0006652296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8579423,0.06567024,0.02548191,0.000405941,0.002927106,0.0003247164,0.0002619918,0.001114837,0.01696172,0.0001088473,0.002136102,0.02666434],"study_design_scores_gemma":[0.5135246,0.4209271,0.0567043,0.00002970318,0.001707183,0.0005206916,0.0001407607,0.00105092,0.00239983,0.0001261854,0.002813128,0.00005558563],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951474,0.0007697896,0.0003244444,0.0001371383,0.0000620149,0.001909216,0.001085198,0.00004304008,0.0005216004],"genre_scores_gemma":[0.9906181,0.0006817139,0.00105335,0.0005515972,0.0001788038,0.002392733,0.002942733,0.00002738748,0.00155369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004384317,"threshold_uncertainty_score":0.01806766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05796847535692534,"score_gpt":0.4249226621907886,"score_spread":0.3669541868338633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}